1. Home
  2. MFA vs ACRS Comparison

MFA vs ACRS Comparison

Compare MFA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFA Financial Inc.

MFA

MFA Financial Inc.

N/A

Current Price

$9.15

Market Cap

957.0M

Sector

Real Estate

ML Signal

N/A

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.93

Market Cap

868.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFA
ACRS
Founded
1997
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
957.0M
868.5M
IPO Year
1998
2015

Fundamental Metrics

Financial Performance
Metric
MFA
ACRS
Price
$9.15
$5.93
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$11.05
$10.20
AVG Volume (30 Days)
1.5M
1.8M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
14.16%
N/A
EPS Growth
58.54
69.01
EPS
0.23
N/A
Revenue
N/A
$1,683,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$10.02
$4.24
P/E Ratio
$39.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.80
$1.70
52 Week High
$10.57
$6.52

Technical Indicators

Market Signals
Indicator
MFA
ACRS
Relative Strength Index (RSI) 46.43 57.90
Support Level $8.90 $4.13
Resistance Level $9.38 $6.52
Average True Range (ATR) 0.17 0.37
MACD 0.01 0.02
Stochastic Oscillator 67.37 59.47

Price Performance

Historical Comparison
MFA
ACRS

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets; and Lima One.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: